Arylquinazolines

1. A compound of formula (I)

in which

X is CH, CF, S or N,

Y is CH, S or N,

Z is C or N,

---- forms, if Z═C, a double bond together with the single bond,

is absent if Z=N,

n is 1 or 2, where

if n=1, X=S, and if n=2, both X=CH, or the X linked to the pyrimidine ring is CF and the X not linked to the pyrimidine ring is CH, or one X is CH and the other X is N;

m is 1 or 2, where

if m=1, Y=S, and if m=2, both Y=CH, or one Y is CH and the other Y is N;

R 1 , R 2 , R 3 , R 4 , independently of one another, are H, Hal, CN, OH, CONH 2 , CONH(LA) or LA;

R 5 is H, Hal, CN or C≡CH;

Cyc is phenyl, which may be unsubstituted or mono- or disubstituted, independently of one another, by R 6 , or is Het 1 ;

Het 1 is a mono- or bicyclic, 5-10-membered heterocycle, having 1-3 N, O or S atoms, or 1-4 N atoms, which may be unsubstituted or mono-, di- or trisubstituted, independently of one another, by R 6 , or may be monosubstituted by Het 2 ;

R 6 is Hal, LA, oxo, CN, or NH 2 ;

LA is unbranched or branched alkyl having 1-5 C atoms, which may be saturated or partially unsaturated, in which 1-3 H atoms may be replaced by Hal, or one H atom may be replaced by CN or Het 2 , or one or two CH 2 groups may be replaced by O, NH, N(CH 3 ) or CO;

Het 2 is a 3-5-membered aliphatic homo- or heterocycle having 0, 1, 2 or 3 N, O or S atoms, which is unsubstituted; and

Hal is F, Cl, Br or I;

wherein any H, C, N, O, P, F, and Cl can be in the form of a heavier isotope thereof;

or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios.

2. The compound according to claim 1 , wherein said compound is of formula (Ib),

or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios.

3. A compound of formula (II)

in which

X is CH, CF, S or N,

Y is CH, S or N,

Z is C or N,

n is 1 or 2, where

if n=1, X=S, and if n=2, both X=CH, or the X linked to the pyrimidine ring is CF and the X not linked to the pyrimidine ring is CH, or one X is CH and the other X is N;

m is 1 or 2, where

if m=1, Y=S, and if m=2, both Y=CH, or one Y is CH and the other Y is N;

R 1 and R 2 independently of one another, are H, Hal, CN, OH, CONH 2 , CONH(LA) or LA;

R 3 is Hal, CN, OH, CONH 2 , CONH(LA) or LA;

R 5 is H, Hal, CN or C≡CH,

LA is unbranched or branched alkyl having 1-5 C atoms, which may be saturated or partially unsaturated, in which 1-3 H atoms may be replaced by Hal, or one H atom may be replaced by CN or Het 2 , or one or two CH 2 groups may be replaced by O, NH, N(CH 3 ) or CO;

Hal is F, Cl, Br or I;

Cyc is Het 1 ;

Het 1 is a mono- or bicyclic, 5-10-membered heterocycle, having 1-3 N, O or S atoms, or 1-4 N atoms, which may be monosubstituted by Het 2 ;

Het 2 is a 3-5-membered aliphatic homo- or heterocycle having 0, 1, 2 or 3 N, O or S atoms, which is unsubstituted;

R 6′ , R 6″ , independently of one another, are H, Hal, LA, oxo, CN, NH 2 or Het 2 ;

Q 1 , Q 2 , independently of one another, are CH, N or NH and are in each case unsubstituted; and

---- denotes the presence or absence of double bonds in Cyc;

or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios.

4. A compound of formula (IIa)

in which

Y is CH, S or N,

R 1 is H, Hal, CN, OH, CONH 2 , CONH(LA) or LA;

LA is unbranched or branched alkyl having 1-5 C atoms, which may be saturated or partially unsaturated, in which 1-3 H atoms may be replaced by Hal, or one H atom may be replaced by CN or Het 2 , or one or two CH 2 groups may be replaced by O, NH, N(CH 3 ) or CO;

Hal is F, Cl, Br or I;

R 2 , R 3 , independently of one another, are Hal, CN, OH, CONH 2 , CON(LA) or LA;

R 5 is H, Hal, CN or C≡CH,

Cyc is Het 1 ;

Het 1 is a mono- or bicyclic, 5-10-membered heterocycle, having 1-3 N, O or S atoms, or 1-4 N atoms, which may be monosubstituted by Het 2 ;

Het 2 is a 3-5-membered aliphatic homo- or heterocycle having 0, 1, 2 or 3 N, O or S atoms, which is unsubstituted;

R 6′ , R 6″ , independently of one another, are H, Hal, LA, oxo, CN, NH 2 or Het 2 ;

Q 1 , Q 2 , independently of one another, are CH, N or NH and are in each case unsubstituted;

X 1 is CH, CF or N;

X 2 is CH or N,

where X 1 , X 2 are not simultaneously N;

Y is CH or N; and

---- denotes the presence or absence of double bonds in Cyc;

or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios.

5. The compound according to claim 3 , wherein said compound is of formula (IIb)

in which

R 2 , R 3 , independently of one another, are Hal, CN, OH, CONH 2 , CON(LA) or LA;

R 6′ , R 6″ , independently of one another, are H, Hal, LA, oxo, CN, NH 2 or Het 2 ;

Q 1 ,Q 2 , independently of one another, are CH, N or NH and are in each case unsubstituted;

Y is CH or N; and

--- denotes the presence or absence of double bonds in Cyc;

or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios.

6. The compound according to claim 4 , wherein one of the following apply:

in the case of the sub-formula (IIa-A)

X 1 is CH,

R 1 is F or Cl, and

R 2 is F or Cl; or

in the case of the sub-formula (IIa-B)

R 1 is F, and

R 2 is F or Cl; or

in the case of the sub-formula (IIa-C)

X 1 , X 2 is CH; or

in the case of the sub-formula (IIa-D)

X 1 is CH, and

R 5 is H

in the case of the sub-formula (IIa-E)

R 3 is OH; or

in the case of the sub-formula (IIa-F)

X 1 is CH, and

R 3 is OH; or

in the case of the sub-formula (IIa-G)

X 1 is CH, and

Y is CH; or

in the case of the sub-formula (IIa-H)

X 1 is CH, and

Cyc is pyridine, pyrazine or pyridazine, or pyrazolo[1,5-a]pyrimidinyl or imidazo[1,2-b]-pyridazinyl; or

in the case of the sub-formula (IIa-J)

Cyc is pyridine, pyrazine, pyridazine, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, furo[2,3-c]pyridinyl, furo[2,3-d}pyridazinyl, thieno[2,3-d}pyridazinyl, thieno[2,3-d}-pyrimidinyl or imidazo[4,5-c]pyridinyl, each of which may be unsubstituted, or may be mono- or disubstituted by methoxy, methyl, oxo, Cl or CHF 2 O; or

in the case of the sub-formula (IIa-K)

R 1 is F or Cl,

R 2 is F or Cl,

R 3 is OH,

R 5 is H, and

X 1 , X 2 is CH; or

in the case of the sub-formula (IIa-L)

R 1 is F,

R 2 is F or Cl,

R 3 is OH, and

R 5 is H; or

in the case of the sub-formula (IIa-M)

R 1 is F or Cl,

R 2 is F or Cl,

R 3 is OH,

R 5 is H,

X 1 , X 2 is CH, and

Cyc is pyridine, pyrazine or pyridazine, or pyrazolo[1,5-a]pyrimidinyl or imidazo[1,2-b]-pyridazinyl; or

in the case of the sub-formula (IIa-N)

R 1 is F,

R 2 is F or Cl,

R 3 is OH,

R 5 is H, and

Cyc is pyridine, pyrazine, pyridazine, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, furo[2,3-c]pyridinyl, furo[2,3-d}pyridazinyl, thieno[2,3-d}pyridazinyl, thieno[2,3-d}-pyrimidinyl or imidazo[4,5-c]pyridinyl, each of which may be unsubstituted, or may be mono- or disubstituted by methoxy, methyl, oxo, Cl or CHF 2 O; or

in the case of the sub-formula (IIa-O)

R 1 is F,

R 2 is F or Cl,

R 3 is OH,

R 5 is H, and

Cyc is 5-methoxypyridazin-3-yl, imidazo[1,2-b]pyridazin-6-yl, 3-chloro-6-methoxypyrazin-2-yl, 3-chloropyrazin-2-yl, pyridazin-4-yl, 3-methoxypyrazin-2-yl, 6-methoxypyridazin-3-yl, 3-difluoromethoxypyridin-2-yl, 3-methylpyrazin-2-yl, thieno[2,3-d}pyrimidin-4-yl, 1-methyl-1H-pyridin-2-one-6-yl, 1H-pyridazin-6-one-3-yl, furo[2,3-d}pyridazin-7-yl, thieno[2,3-d}pyridazin-7-yl, 3,5-dimethylpyrazin-2-yl, furo[2,3-d}pyrimidin-4-yl, 3-methyl-3H-imidazo[4,5-c]pyridin-4-yl; or

or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios.

7. The compound according to claim 5 , but in which

in the case of the sub-formula (IIb-Q)

R 1 is F or Cl,

R 2 is F or Cl,

R 3 is OH,

R 5 is H, and

Y is CH; or

the case of the sub-formula (IIb-R)

R 1 is F,

R 2 is F or Cl,

R 3 is OH,

R 5 is H, and

Y is CH; or

in the case of the sub-formula (IIb-S)

Cyc is pyridine, pyrazine or pyridazine; or

in the case of the sub-formula (IIb-T)

R 1 is F or Cl,

R 2 is F or Cl,

R 3 is OH,

R 5 is H, and

Cyc is pyridine, pyrazine or pyridazine; or

in the case of the sub-formula (IIb-U)

R 1 is F,

R 2 is F or Cl,

R 3 is OH,

R 5 is H, and

Cyc is pyridine, pyrazine, pyridazine or 3-methylpyrazin-2-yl; or

or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios.

8. The compound according to claim 1 , wherein said compound is selected from the following:

[2-Chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(5-methoxypyridazin-3-yl)-methanol,

[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(5-methoxypyridazin-3-yl)methanol,

[2,4-Difluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]imidazo[1,2-b]pyridazin-6-yl-methanol,

(3-Chloro-6-methoxypyrazin-2-yl)-[4-fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-methanol,

(R)-(3-Chloropyrazin-2-yl)-[4-fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]methanol,

[2-Chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]pyridazin-4-ylmethanol,

[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methoxypyrazin-2-yl)methanol,

[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol,

(3-Difluoromethoxypyridin-2-yl)-[4-fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-methanol,

(R)-[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methylpyrazin-2-yl)methanol,

[2,4-Difluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methylpyrazin-2-yl)methanol,

[2,4-Difluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]thieno[2,3-d}pyrimidin-4-ylmethanol,

6-{[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]hydroxymethyl}-1-methyl-1H-pyridin-2-one,

3-[[2-Chloro-4-fluoro-5-(7-morpholinoquinazolin-4-yl)phenyl]hydroxymethyl]-1H-pyridazin-6-one,

(S)-[2-Chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)-methanol,

(R)-[4-Fluoro-3-(7-morpholin-4-ylpyrido[3,2-d]pyrimidin-4-yl)phenyl]-(3-methylpyrazin-2-yl)-methanol,

4-(4-Chloro-2-fluoro-5-imidazo[1,2-b]pyridazin-6-ylmethylphenyl)-7-morpholin-4-yl-quinazoline,

[4-Fluoro-3-(6-morpholin-4-ylthieno[3,2-d}pyrimidin-4-yl)phenyl]-(3-methylpyrazin-2-yl)-methanol,

(R)-[4-Fluoro-3-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methylpyrazin-2-yl)-methanol,

[2-Chloro-4-fluoro-5-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methoxypyrazin-2-yl)methanol,

[4-Fluoro-3-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methoxypyrazin-2-yl)-methanol,

[4-Fluoro-3-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)-methanol,

[4-Fluoro-3-[7-(2,2,3,3,5,5,6,6-octadeuteriomorpholin-4-yl)quinazolin-4-yl]phenyl]-(3-methylpyrazin-2-yl)methanol,

[4-Fluoro-3-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)-methanol,

[2-Chloro-4-fluoro-5-[7-(2,2,3,3,5,5,6,6-octadeuteriomorpholin-4-yl)quinazolin-4-yl]phenyl]-(6-methoxypyridazin-3-yl)methanol,

[2-Chloro-4-fluoro-5-(6-morpholin-4-ylthieno[3,2-d}pyrimidin-4-yl)phenyl]-(3-methylpyrazin-2-yl)methanol,

[4-Fluoro-3-(6-morpholin-4-ylthieno[3,2-d}pyrimidin-4-yl)phenyl]-(3-methylpyrazin-2-yl)-methanol,

[2-Chloro-4-fluoro-5-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methoxypyrazin-2-yl)methanol,

[4-Fluoro-3-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methoxypyrazin-2-yl)-methanol,

[4-Fluoro-3-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methylpyrazin-2-yl)-methanol,

[2-Chloro-4-fluoro-5-(5-fluoro-7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol,

[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]furo[2,3-d}pyridazin-7-ylmethanol,

[2,4-Difluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]furo[2,3-d}pyridazin-7-ylmethanol,

[2,4-Difluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]thieno[2,3-d}pyridazin-7-ylmethanol,

(3,5-Dimethylpyrazin-2-yl)-[4-fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]methanol,

6-{[2-Chloro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]hydroxymethyl}-1-methyl-1H-pyridin-2-one,

6-{[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]hydroxymethyl}-2H-pyridazin-3-one,

6-{[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]hydroxymethyl}-1-methyl-1H-pyridin-2-one,

6-{[2-Chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]hydroxymethyl}-1-methyl-1H-pyridin-2-one,

[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]furo[2,3-d}pyrimidin-4-ylmethanol,

[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]furo[3,2-d}pyrimidin-4-ylmethanol,

[2,4-Difluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methoxypyrazin-2-yl)methanol,

4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(3-methyl-3H-imidazo[4,5-c]pyridin-4-yl)methanol, or

[4-Fluoro-3-(7-morpholin-4-ylquinazolin-4-yl)phenyl]furo[3,2-d}pyrimidin-4-ylmethanol,

or a physiologically acceptable salt, tautomer or stereoisomer thereof,

including mixtures thereof in all ratios.

9. A pharmaceutical composition comprising, as active compound, an effective amount of at least one compound according to claim 1 or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios, together with pharmaceutically tolerated adjuvants.

10. The pharmaceutical composition according to claim 9 , further comprising an effective amount of at least one additional anticancer agent.

11. A kit comprising separate packs of (a) an effective amount of at least one compound according to claim 1 or a physiologically acceptable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios, and (b) an effective amount of at least additional one anticancer agent.

12. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising, as active compound, an effective amount of at least one compound according to claim 12 or a physiologically acceptable salt thereof, including mixtures thereof in all ratios, together with pharmaceutically tolerated adjuvants.

14. The pharmaceutical composition according to claim 13 , further comprising an effective amount of at least one additional anticancer agent.